Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
Status:
Completed
Trial end date:
2018-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the initial tolerability, safety and recommended phase
2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard
GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell
transplantation [allo-HSCT]).